We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+11.59%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$251M
AUM Growth
-$21.6M
(-7.9%)
Cap. Flow
-$35.8M
Cap. Flow
% of AUM
-14.23%
Top 10 Holdings %
Top 10 Hldgs %
56.38%
Holding
35
New
4
Increased
11
Reduced
10
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SEM
Select Medical
SEM
|
+$10M |
| 2 |
ENZY
Enzymotec Ltd
ENZY
|
+$6.63M |
| 3 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$6.33M |
| 4 |
West Pharmaceutical
WST
|
+$5.36M |
| 5 |
ResMed
RMD
|
+$4.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$13.9M |
| 2 |
Medtronic
MDT
|
+$11.2M |
| 3 |
Accuray
ARAY
|
+$9.7M |
| 4 |
MGLN
Magellan Health Services, Inc.
MGLN
|
+$7.92M |
| 5 |
ITMN
INTERMUNE INC
ITMN
|
+$7.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.4% |
| 2 | Miscellaneous | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
AbbVie
ABBV
$454B
| – | – |
-245,901
| Closed | -$13.9M |
|
|
27
Accuray
ARAY
$29.9M
| – | – |
-1,102,494
| Closed | -$9.7M |
|
28
Incyte
INCY
$24.6B
| – | – |
-9,420
| Closed | -$532K |
|
|
29
Medtronic
MDT
$116B
| – | – |
-175,824
| Closed | -$11.2M |
|
30
Orthofix Medical
OFIX
$364M
| – | – |
-85,238
| Closed | -$3.09M |
|
31
Tandem Diabetes Care
TNDM
$1.19B
| – | – |
-21,425
| Closed | -$3.48M |
|
32
CALL
Zoetis
ZTS
$30.2B
| – | – |
-380,000
| Closed | -$12.3M |
|
|
MGLN
33
DELISTED
Magellan Health Services, Inc.
MGLN
| – | – |
-127,180
| Closed | -$7.92M |
|
|
ITMN
34
DELISTED
INTERMUNE INC
ITMN
| – | – |
-175,422
| Closed | -$7.75M |
|
|
AGN
35
DELISTED
Allergan Inc
AGN
| – | – |
-32,336
| Closed | -$5.47M |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q3 2014 Portfolio in Review
As of Q3 2014, March Altus Capital Management held 35 positions worth $251M, down 7.9% from $273M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
March Altus Capital Management withdrew a net $35.8M in Q3 2014, closing 10 positions and reducing 10 holdings. Its most notable exit was AbbVie, an estimated $13.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Miscellaneous.
Against the trend, March Altus Capital Management opened a new position in Select Medical worth $8.4M.
- March Altus Capital Management's largest Q3 2014 buy was Select Medical: 1,295,778 shares worth $8.4M.
- March Altus Capital Management added most to Enzymotec Ltd in Q3 2014, an estimated $6.63M increase.
- March Altus Capital Management's biggest Q3 2014 reduction was United Therapeutics, cutting an estimated $7.68M.
- March Altus Capital Management fully exited AbbVie in Q3 2014, selling an estimated $13.9M.
- March Altus Capital Management's ten largest holdings make up 56% of its $251M portfolio in Q3 2014.
- March Altus Capital Management opened 4 new positions and closed 10 in Q3 2014.
- March Altus Capital Management's portfolio value fell 7.9% quarter-over-quarter to $251M.
Based on March Altus Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.